Table 1 Clinical features of the study population (n = 52).
Variable | Patients, n (%) |
|---|---|
Menopausal stage at diagnosis: | |
• Premenopausal | 17 (32.7) |
• Postmenopausal | 34 (65.4) |
• Unknown | 1 (1.9) |
ECOG PS at the time of advanced disease diagnosis: | |
• 0 | 40 (77) |
• 1 | 8 (15.4) |
• 2 | 1 (1.9) |
• Unknown | 3 (5.7) |
BRCA1/2 status: | |
• Positive | 8 (15.4) |
• Negative | 29 (55.8) |
• Unknown | 15 (28.8) |
Disease stage at initial diagnosis: | |
• 1 | 4 (7.7) |
• 2 | 15 (28.8) |
• 3 | 22 (42.3) |
• 4 | 11 (21.1) |
Surgery of the primarya | 44 (84.6) |
Previous systemic therapy | |
Total patients | 41 (78.8) |
• Only neoadjuvant chemotherapy | 15 (36.6) |
• Only adjuvant chemotherapy | 18 (43.9) |
• Both neoadjuvant and adjuvant chemotherapy | 7 (17.1) |
• Nihil | 1 (2.4) |
Previous neo/adjuvant chemotherapy regimen: | |
• Anthracyclines | 36 (69.2) |
• Taxane | 34 (65.4) |
• Carboplatin | 8 (15.4) |
Number of metastatic sites: | |
• 1 | 29 (55.8) |
• 2 | 17 (32.7) |
• ≥3 | 6 (11.5) |
Site of metastasis at the time of advanced disease diagnosis: | |
• Liver | 7 (13.5) |
• Lung | 25 (48.1) |
• Bone | 9 (17.3) |
• Soft tissue | 34 (65.4) |
• Brain | 2 (3.8) |
Dominant site of metastasis: | |
• Liver | 7 (13.5) |
• Lung | 24 (46.2) |
• Bone | 5 (9.6) |
• Soft tissue | 16 (30.8) |
